Health Canada Approval of BioCloud I would hope that this recent "blitz" of BioCloud promotion by Ghezzi and Co is based on their clear understanding and knowledge that HC approval is a slam dunk. In other words, HC has already informally confirmed with Ghezzi and Co that approval is imminent. If that is the case, I believe the formal approval of BioCloud will be reased by HC shortly and therefore now should be a good time to start putting your money to work on buying some or more KNR shares. A bigger catalyst would be confirmation of meaningful BioCloud sales volumes. At a market cap of only 80M$ Cdn shares are considered very, very cheap especially if the full year 2021 revenue forecast identified by Ghezzi (I believe approx 40M$?) Comes to fruition. If it does, using a 5X sales multiple values KNR shares at a price of approx $4.50 versus the $1.83 close today. Your guess is as good as mine whether the ~40M$ is reliable and whether BioCloud forecasted sales are even in these numbers. I don't think there is a big BioCloud component....Regardless, take the above for what it is worth. KNR shares look cheap at current levels. Surprisingly cheap based on the prospects that appear before us.....